Exploring mechanisms of psychedelic action using neuroimaging

被引:7
|
作者
David Erritzoe
Christopher Timmermann
Kate Godfrey
Pedro Castro-Rodrigues
Joseph Peill
Robin L. Carhart-Harris
David J. Nutt
Matthew B. Wall
机构
[1] Imperial College London,Division of Psychiatry, Faculty of Medicine
[2] Imperial College London,Centre for Psychedelic Research and Neuropsychopharmacology
[3] Centro Hospitalar Psiquiátrico de Lisboa,undefined
[4] University of California,undefined
[5] Invicro,undefined
来源
Nature Mental Health | 2024年 / 2卷 / 2期
关键词
D O I
10.1038/s44220-023-00172-3
中图分类号
学科分类号
摘要
Modern psychedelic research and clinical development is at a crucial inflection point, with great potential for the treatment of many mental illnesses demonstrated but significant questions that remain unresolved. Neuroimaging has been pivotal in the modern era of psychedelic research, providing crucial insights into the acute effects of these drugs that revealed translational, clinical potential. Here we review this evidence from functional magnetic resonance imaging, positron emission tomography and magnetoencephalography/electroencephalography studies and describe how these findings inform computational models of both the acute action of psychedelics and their longer-term therapeutic effects. This approach, based on multi-modal neuroimaging, provides a solid evidence base for these therapies as they move forwards, as well as a fuller understanding of the powerful effects of psychedelics on the phenomenology of human consciousness.
引用
收藏
页码:141 / 153
页数:12
相关论文
共 50 条
  • [1] Using Functional Neuroimaging to Investigate the Mechanisms of Action of Selective Serotonin Reuptake Inhibitors (SSRIs)
    Murphy, Susannah E.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (18) : 1990 - 1997
  • [2] Exploring mechanisms of action in clinical trials of complex interventions using mediation
    Sharples, Linda
    Rex, Saleema
    Papachristofi, Olympia
    TRIALS, 2019, 20
  • [3] Neuroimaging in psychedelic drug development: past, present, and future
    Wall, Matthew B.
    Harding, Rebecca
    Zafar, Rayyan
    Rabiner, Eugenii A.
    Nutt, David J.
    Erritzoe, David
    MOLECULAR PSYCHIATRY, 2023, 28 (09) : 3573 - 3580
  • [4] Neuroimaging in psychedelic drug development: past, present, and future
    Matthew B. Wall
    Rebecca Harding
    Rayyan Zafar
    Eugenii A. Rabiner
    David J. Nutt
    David Erritzoe
    Molecular Psychiatry, 2023, 28 : 3573 - 3580
  • [5] The neural basis of psychedelic action
    Alex C. Kwan
    David E. Olson
    Katrin H. Preller
    Bryan L. Roth
    Nature Neuroscience, 2022, 25 : 1407 - 1419
  • [6] Examining psychedelic drug action
    D. Dewran Kocak
    Bryan L. Roth
    Nature Chemistry, 2024, 16 : 142 - 142
  • [7] Understanding psychedelic antidepressant action
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (04) : 271 - 271
  • [8] Examining psychedelic drug action
    Kocak, D. Dewran
    Roth, Bryan L.
    NATURE CHEMISTRY, 2024, 16 (01) : 142 - 142
  • [9] Understanding psychedelic antidepressant action
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2023, 22 : 271 - 271
  • [10] The neural basis of psychedelic action
    Kwan, Alex C.
    Olson, David E.
    Preller, Katrin H.
    Roth, Bryan L.
    NATURE NEUROSCIENCE, 2022, 25 (11) : 1407 - 1419